Cargando…
Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER)
The impacts of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic on cancer care are multiple, entailing a high risk of death from coronavirus disease 2019 (COVID-19) in patients with cancer treated by chemotherapy. SARS-CoV-2 vaccines represent an opportunity to decrease the...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8015403/ https://www.ncbi.nlm.nih.gov/pubmed/33934060 http://dx.doi.org/10.1016/j.ejca.2021.03.030 |
_version_ | 1783673671355727872 |
---|---|
author | Tougeron, David Hentzien, Maxime Seitz-Polski, Barbara Bani-Sadr, Firouze Bourhis, Jean Ducreux, Michel Gaujoux, Sébastien Gorphe, Philippe Guiu, Boris Hoang-Xuan, Khê Huguet, Florence Lecomte, Thierry Lièvre, Astrid Louvet, Christophe Maggiori, Léon Mansi, Laura Mariani, Pascale Michel, Pierre Servettaz, Amélie Thariat, Juliette Westeel, Virgine Aparicio, Thomas Blay, Jean-Yves Bouché, Olivier |
author_facet | Tougeron, David Hentzien, Maxime Seitz-Polski, Barbara Bani-Sadr, Firouze Bourhis, Jean Ducreux, Michel Gaujoux, Sébastien Gorphe, Philippe Guiu, Boris Hoang-Xuan, Khê Huguet, Florence Lecomte, Thierry Lièvre, Astrid Louvet, Christophe Maggiori, Léon Mansi, Laura Mariani, Pascale Michel, Pierre Servettaz, Amélie Thariat, Juliette Westeel, Virgine Aparicio, Thomas Blay, Jean-Yves Bouché, Olivier |
author_sort | Tougeron, David |
collection | PubMed |
description | The impacts of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic on cancer care are multiple, entailing a high risk of death from coronavirus disease 2019 (COVID-19) in patients with cancer treated by chemotherapy. SARS-CoV-2 vaccines represent an opportunity to decrease the rate of severe COVID-19 cases in patients with cancer and also to restore normal cancer care. Patients with cancer to be targeted for vaccination are difficult to define owing to the limited contribution of these patients in the phase III trials testing the different vaccines. It seems appropriate to vaccinate not only patients with cancer with ongoing treatment or with a treatment having been completed less than 3 years ago but also household and close contacts. High-risk patients with cancer who are candidates for priority access to vaccination are those treated by chemotherapy. The very high-priority population includes patients with curative treatment and palliative first- or second-line chemotherapy, as well as patients requiring surgery or radiotherapy involving a large volume of lung, lymph node and/or haematopoietic tissue. When possible, vaccination should be carried out before cancer treatment begins. SARS-CoV-2 vaccination can be performed during chemotherapy while avoiding periods of neutropenia and lymphopenia. For organisational reasons, vaccination should be performed in cancer care centres with messenger RNA vaccines (or non-replicating adenoviral vaccines in non-immunocompromised patients). Considering the current state of knowledge, the benefit-risk ratio strongly favours SARS-CoV-2 vaccination of all patients with cancer. To obtain more data concerning the safety and effectiveness of vaccines, it is necessary to implement cohorts of vaccinated patients with cancer. |
format | Online Article Text |
id | pubmed-8015403 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80154032021-04-02 Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER) Tougeron, David Hentzien, Maxime Seitz-Polski, Barbara Bani-Sadr, Firouze Bourhis, Jean Ducreux, Michel Gaujoux, Sébastien Gorphe, Philippe Guiu, Boris Hoang-Xuan, Khê Huguet, Florence Lecomte, Thierry Lièvre, Astrid Louvet, Christophe Maggiori, Léon Mansi, Laura Mariani, Pascale Michel, Pierre Servettaz, Amélie Thariat, Juliette Westeel, Virgine Aparicio, Thomas Blay, Jean-Yves Bouché, Olivier Eur J Cancer Current Perspective The impacts of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic on cancer care are multiple, entailing a high risk of death from coronavirus disease 2019 (COVID-19) in patients with cancer treated by chemotherapy. SARS-CoV-2 vaccines represent an opportunity to decrease the rate of severe COVID-19 cases in patients with cancer and also to restore normal cancer care. Patients with cancer to be targeted for vaccination are difficult to define owing to the limited contribution of these patients in the phase III trials testing the different vaccines. It seems appropriate to vaccinate not only patients with cancer with ongoing treatment or with a treatment having been completed less than 3 years ago but also household and close contacts. High-risk patients with cancer who are candidates for priority access to vaccination are those treated by chemotherapy. The very high-priority population includes patients with curative treatment and palliative first- or second-line chemotherapy, as well as patients requiring surgery or radiotherapy involving a large volume of lung, lymph node and/or haematopoietic tissue. When possible, vaccination should be carried out before cancer treatment begins. SARS-CoV-2 vaccination can be performed during chemotherapy while avoiding periods of neutropenia and lymphopenia. For organisational reasons, vaccination should be performed in cancer care centres with messenger RNA vaccines (or non-replicating adenoviral vaccines in non-immunocompromised patients). Considering the current state of knowledge, the benefit-risk ratio strongly favours SARS-CoV-2 vaccination of all patients with cancer. To obtain more data concerning the safety and effectiveness of vaccines, it is necessary to implement cohorts of vaccinated patients with cancer. Elsevier Ltd. 2021-06 2021-04-01 /pmc/articles/PMC8015403/ /pubmed/33934060 http://dx.doi.org/10.1016/j.ejca.2021.03.030 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Current Perspective Tougeron, David Hentzien, Maxime Seitz-Polski, Barbara Bani-Sadr, Firouze Bourhis, Jean Ducreux, Michel Gaujoux, Sébastien Gorphe, Philippe Guiu, Boris Hoang-Xuan, Khê Huguet, Florence Lecomte, Thierry Lièvre, Astrid Louvet, Christophe Maggiori, Léon Mansi, Laura Mariani, Pascale Michel, Pierre Servettaz, Amélie Thariat, Juliette Westeel, Virgine Aparicio, Thomas Blay, Jean-Yves Bouché, Olivier Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER) |
title | Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER) |
title_full | Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER) |
title_fullStr | Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER) |
title_full_unstemmed | Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER) |
title_short | Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER) |
title_sort | severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: review and point of view of a french oncology intergroup (gco, tncd, unicancer) |
topic | Current Perspective |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8015403/ https://www.ncbi.nlm.nih.gov/pubmed/33934060 http://dx.doi.org/10.1016/j.ejca.2021.03.030 |
work_keys_str_mv | AT tougerondavid severeacuterespiratorysyndromecoronavirus2vaccinationforpatientswithsolidcancerreviewandpointofviewofafrenchoncologyintergroupgcotncdunicancer AT hentzienmaxime severeacuterespiratorysyndromecoronavirus2vaccinationforpatientswithsolidcancerreviewandpointofviewofafrenchoncologyintergroupgcotncdunicancer AT seitzpolskibarbara severeacuterespiratorysyndromecoronavirus2vaccinationforpatientswithsolidcancerreviewandpointofviewofafrenchoncologyintergroupgcotncdunicancer AT banisadrfirouze severeacuterespiratorysyndromecoronavirus2vaccinationforpatientswithsolidcancerreviewandpointofviewofafrenchoncologyintergroupgcotncdunicancer AT bourhisjean severeacuterespiratorysyndromecoronavirus2vaccinationforpatientswithsolidcancerreviewandpointofviewofafrenchoncologyintergroupgcotncdunicancer AT ducreuxmichel severeacuterespiratorysyndromecoronavirus2vaccinationforpatientswithsolidcancerreviewandpointofviewofafrenchoncologyintergroupgcotncdunicancer AT gaujouxsebastien severeacuterespiratorysyndromecoronavirus2vaccinationforpatientswithsolidcancerreviewandpointofviewofafrenchoncologyintergroupgcotncdunicancer AT gorphephilippe severeacuterespiratorysyndromecoronavirus2vaccinationforpatientswithsolidcancerreviewandpointofviewofafrenchoncologyintergroupgcotncdunicancer AT guiuboris severeacuterespiratorysyndromecoronavirus2vaccinationforpatientswithsolidcancerreviewandpointofviewofafrenchoncologyintergroupgcotncdunicancer AT hoangxuankhe severeacuterespiratorysyndromecoronavirus2vaccinationforpatientswithsolidcancerreviewandpointofviewofafrenchoncologyintergroupgcotncdunicancer AT huguetflorence severeacuterespiratorysyndromecoronavirus2vaccinationforpatientswithsolidcancerreviewandpointofviewofafrenchoncologyintergroupgcotncdunicancer AT lecomtethierry severeacuterespiratorysyndromecoronavirus2vaccinationforpatientswithsolidcancerreviewandpointofviewofafrenchoncologyintergroupgcotncdunicancer AT lievreastrid severeacuterespiratorysyndromecoronavirus2vaccinationforpatientswithsolidcancerreviewandpointofviewofafrenchoncologyintergroupgcotncdunicancer AT louvetchristophe severeacuterespiratorysyndromecoronavirus2vaccinationforpatientswithsolidcancerreviewandpointofviewofafrenchoncologyintergroupgcotncdunicancer AT maggiorileon severeacuterespiratorysyndromecoronavirus2vaccinationforpatientswithsolidcancerreviewandpointofviewofafrenchoncologyintergroupgcotncdunicancer AT mansilaura severeacuterespiratorysyndromecoronavirus2vaccinationforpatientswithsolidcancerreviewandpointofviewofafrenchoncologyintergroupgcotncdunicancer AT marianipascale severeacuterespiratorysyndromecoronavirus2vaccinationforpatientswithsolidcancerreviewandpointofviewofafrenchoncologyintergroupgcotncdunicancer AT michelpierre severeacuterespiratorysyndromecoronavirus2vaccinationforpatientswithsolidcancerreviewandpointofviewofafrenchoncologyintergroupgcotncdunicancer AT servettazamelie severeacuterespiratorysyndromecoronavirus2vaccinationforpatientswithsolidcancerreviewandpointofviewofafrenchoncologyintergroupgcotncdunicancer AT thariatjuliette severeacuterespiratorysyndromecoronavirus2vaccinationforpatientswithsolidcancerreviewandpointofviewofafrenchoncologyintergroupgcotncdunicancer AT westeelvirgine severeacuterespiratorysyndromecoronavirus2vaccinationforpatientswithsolidcancerreviewandpointofviewofafrenchoncologyintergroupgcotncdunicancer AT apariciothomas severeacuterespiratorysyndromecoronavirus2vaccinationforpatientswithsolidcancerreviewandpointofviewofafrenchoncologyintergroupgcotncdunicancer AT blayjeanyves severeacuterespiratorysyndromecoronavirus2vaccinationforpatientswithsolidcancerreviewandpointofviewofafrenchoncologyintergroupgcotncdunicancer AT boucheolivier severeacuterespiratorysyndromecoronavirus2vaccinationforpatientswithsolidcancerreviewandpointofviewofafrenchoncologyintergroupgcotncdunicancer AT severeacuterespiratorysyndromecoronavirus2vaccinationforpatientswithsolidcancerreviewandpointofviewofafrenchoncologyintergroupgcotncdunicancer AT severeacuterespiratorysyndromecoronavirus2vaccinationforpatientswithsolidcancerreviewandpointofviewofafrenchoncologyintergroupgcotncdunicancer AT severeacuterespiratorysyndromecoronavirus2vaccinationforpatientswithsolidcancerreviewandpointofviewofafrenchoncologyintergroupgcotncdunicancer AT severeacuterespiratorysyndromecoronavirus2vaccinationforpatientswithsolidcancerreviewandpointofviewofafrenchoncologyintergroupgcotncdunicancer AT severeacuterespiratorysyndromecoronavirus2vaccinationforpatientswithsolidcancerreviewandpointofviewofafrenchoncologyintergroupgcotncdunicancer AT severeacuterespiratorysyndromecoronavirus2vaccinationforpatientswithsolidcancerreviewandpointofviewofafrenchoncologyintergroupgcotncdunicancer AT severeacuterespiratorysyndromecoronavirus2vaccinationforpatientswithsolidcancerreviewandpointofviewofafrenchoncologyintergroupgcotncdunicancer AT severeacuterespiratorysyndromecoronavirus2vaccinationforpatientswithsolidcancerreviewandpointofviewofafrenchoncologyintergroupgcotncdunicancer AT severeacuterespiratorysyndromecoronavirus2vaccinationforpatientswithsolidcancerreviewandpointofviewofafrenchoncologyintergroupgcotncdunicancer AT severeacuterespiratorysyndromecoronavirus2vaccinationforpatientswithsolidcancerreviewandpointofviewofafrenchoncologyintergroupgcotncdunicancer AT severeacuterespiratorysyndromecoronavirus2vaccinationforpatientswithsolidcancerreviewandpointofviewofafrenchoncologyintergroupgcotncdunicancer AT severeacuterespiratorysyndromecoronavirus2vaccinationforpatientswithsolidcancerreviewandpointofviewofafrenchoncologyintergroupgcotncdunicancer AT severeacuterespiratorysyndromecoronavirus2vaccinationforpatientswithsolidcancerreviewandpointofviewofafrenchoncologyintergroupgcotncdunicancer AT severeacuterespiratorysyndromecoronavirus2vaccinationforpatientswithsolidcancerreviewandpointofviewofafrenchoncologyintergroupgcotncdunicancer AT severeacuterespiratorysyndromecoronavirus2vaccinationforpatientswithsolidcancerreviewandpointofviewofafrenchoncologyintergroupgcotncdunicancer AT severeacuterespiratorysyndromecoronavirus2vaccinationforpatientswithsolidcancerreviewandpointofviewofafrenchoncologyintergroupgcotncdunicancer |